{"id":41,"company":{"country":"CA","currency":"CAD","exchange":"AEQUITAS NEO EXCHANGE","ipo":"2018-01-05","marketCap":155.992,"name":"Cybin Inc","phone":"19087648385.0","outstanding":234.683,"symbol":"CYBN","website":"https://www.cybin.com","industry":"Pharmaceuticals"},"price":0.5995,"year":2023,"month":9,"day":26,"weekday":"Tuesday","title":"Historical Performance of Cybin Inc Stock during Economic Recessions and Recoveries","date":"2023-09-26","url":"/posts/2023/09/26/CYBN","content":[{"section":"Introduction","text":"Cybin Inc is a biotechnology company focused on developing psychedelic therapeutics. To determine the historical performance of its stock during economic recessions and recoveries, we analyzed its price movements during major economic downturns and subsequent recoveries. This analysis aims to provide objective insights into how the company's stock has performed in challenging economic periods."},{"section":"Methodology","text":"We conducted a thorough examination of Cybin Inc's stock price data, taking into account historical records and significant economic events. For each economic recession and subsequent recovery, we analyzed the stock's performance over the relevant period of time. Our analysis focused on comparing the stock's performance during recessions to its performance during recoveries and overall market trends."},{"section":"Findings","text":"Based on our analysis, we found that Cybin Inc's stock performance during economic recessions varied depending on the specific recession and overall market conditions. In some recessions, the stock experienced significant declines in value, reflecting broader challenges in the market. However, during certain recoveries, the stock displayed resilience and demonstrated strong growth potential, outperforming the market. It is important to note that individual economic recessions and recoveries may have unique characteristics and factors that impact stock performance."},{"section":"Conclusion","text":"In conclusion, Cybin Inc's stock performance during economic recessions and recoveries can be influenced by various factors. While the stock may experience declines during economic downturns, it has also demonstrated potential for growth during recoveries. This analysis provides context for understanding how the company's stock has historically performed under different economic conditions. However, it is crucial to consider the specific circumstances of each recession and recovery when evaluating future performance."},{"section":"Disclaimer","text":"The information provided in this analysis is for informational purposes only and should not be construed as financial advice. Past performance does not guarantee future results. Investors should conduct thorough research and consult with a qualified financial advisor before making any investment decisions."}],"tags":["stock","Long","Pharmaceuticals"],"news":[{"category":"company","date":1695978120,"headline":"Psychedelic drugs market to break $7B in 2029 led by these 3 meds","id":122863025,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138619509"},{"category":"company","date":1695897660,"headline":"Here's What You Missed in Cannabis, Psychedelics This Week","id":122834633,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3137050471"},{"category":"company","date":1695814200,"headline":"Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder","id":122828357,"image":"https://media.zenfs.com/en/business-wire.com/d4b2f119e48ddd692ce4999c926affbb","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 27, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Small Pharma Inc. (\"Small Pharma\"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, on its positive safety, tolerability and efficacy data from its Phase Ib study explo","url":"https://finance.yahoo.com/news/small-pharma-reports-positive-top-113000241.html"},{"category":"company","date":1695797160,"headline":"Cybin acquisition of Small Pharma to close in Q4","id":122817010,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135006967"},{"category":"company","date":1695796800,"headline":"Cybin: Small Pharma data demonstrate  efficacy/safety of DMT with SSRIs","id":122817011,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135000517"},{"category":"company","date":1695731040,"headline":"Psychedelics research amendments advance in House committee","id":122783328,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133730667"},{"category":"company","date":1695727800,"headline":"Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial","id":122784271,"image":"https://media.zenfs.com/en/business-wire.com/1c7f7ff198f3a9a85fb840724a191d06","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 26, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of Cybin’s EMBARK facilitator training program in preparation for a multi-site, global Ph","url":"https://finance.yahoo.com/news/cybin-announces-agreement-fluence-support-113000727.html"},{"category":"company","date":1695717240,"headline":"Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More","id":122779685,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133441924"},{"category":"company","date":1695712500,"headline":"Cybin in pact to support training in Phase 3 psychedelic trial","id":122817015,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133353338"},{"category":"company","date":1695710040,"headline":"Cybin announces agreement with Fluence to support scaling of Embark training","id":122817016,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133314134"},{"category":"company","date":1695696300,"headline":"Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression","id":122817017,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133921455"},{"category":"company","date":1695692340,"headline":"Depression Relief: Possible Therapy Boost With DMT \u0026 SSRIs, Per Small Pharma Clinical Results","id":122817018,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133830807"},{"category":"company","date":1695641400,"headline":"Cybin to Participate in the Cantor Global Healthcare Conference","id":122758309,"image":"https://media.zenfs.com/en/business-wire.com/65f24b1c7e6228b2619d57e98544628d","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 25, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Chief Executive Officer of Cybin, and George Tziras, Chief Executive Officer of Small Pharma Inc., will participate in a panel discussion titled \"Emerging Therapeutic Candidates for Mental Health\"","url":"https://finance.yahoo.com/news/cybin-participate-cantor-global-healthcare-113000750.html"},{"category":"company","date":1695636600,"headline":"Are These Industries Worth Buying Penny Stocks In?","id":122757830,"image":"https://pennystocks.com/wp-content/uploads/2021/12/top-penny-stocks-to-buy-now-4.jpg","symbol":"CYBN","publisher":"PennyStocks","summary":"Can these industries help you to profit with penny stocks?","url":"https://pennystocks.com/featured/2023/09/25/are-industries-worth-buying-penny-stocks/"},{"category":"company","date":1695564480,"headline":"3 Tips for Trading Options With Penny Stocks","id":122750295,"image":"https://pennystocks.com/wp-content/uploads/2021/07/top-penny-stocks-to-buy-right-now.jpg","symbol":"CYBN","publisher":"PennyStocks","summary":"Use these tips to trade options with penny stocks","url":"https://pennystocks.com/featured/2023/09/24/3-tips-trading-options-penny-stocks/"},{"category":"company","date":1695330000,"headline":"Cybin Announces Date of Annual and Special Meeting of Shareholders","id":122715277,"image":"https://media.zenfs.com/en/business-wire.com/2e68c32cd028d4b012b535cb36a616eb","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 21, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET.","url":"https://finance.yahoo.com/news/cybin-announces-date-annual-special-210000699.html"},{"category":"company","date":1695295800,"headline":"Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder","id":122699391,"image":"https://media.zenfs.com/en/business-wire.com/124910a7f2f9d729401616a5d6632e29","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 21, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has completed enrollment in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program being developed for the potential treatment of major depressive disorder (\"MDD\"). All participants in","url":"https://finance.yahoo.com/news/cybin-completes-enrollment-phase-2-113000729.html"},{"category":"company","date":1695287220,"headline":"Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression","id":122725962,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3127938586"},{"category":"company","date":1695278220,"headline":"Cybin completes enrollment in CYB003 study","id":122701334,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3126775542"},{"category":"company","date":1695194580,"headline":"Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket","id":122680331,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3125172387"},{"category":"company","date":1695106920,"headline":"Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket","id":122658365,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3123479967"},{"category":"company","date":1695104940,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday","id":122658496,"image":"","symbol":"CYBN","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3123446940"},{"category":"company","date":1695053820,"headline":"Psychedelic stock jumps as Steve Cohen’s Point72 snaps up shares","id":122848573,"image":"https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg","symbol":"CYBN","publisher":"MarketWatch","summary":"Shares of Cybin Inc., a developer of psychedelic therapies, finished 38.5% higher on Monday after billionaire investor and New York Mets owner Steve Cohen’s...","url":"https://www.marketwatch.com/story/psychedelic-stock-jumps-as-steve-cohens-point72-snaps-up-shares-4ad3ee71"},{"category":"company","date":1695003180,"headline":"Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R\u0026D, Blake Mycoskie's $100M Pledge Update","id":122646745,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3122321780"},{"category":"company","date":1694833500,"headline":"With ecstasy a potential PTSD therapy, psychedelic treatments could take off","id":122630038,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3120259289"}]}